MASCT by Hengrui Yuanzheng Biotechnology for Metastatic Colorectal Cancer: Likelihood of Approval

MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Metastatic Colorectal Cancer.

Cannabis Earnings Season Is About to Begin

The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis companies. This update is our first since

October 30, 2024

Lilly strikes deal with QurAlis for preclinical ALS candidate – Pharmaceutical Technology

Eli Lilly will pay QurAlis a $45m upfront payment for QRL-204, a preclinical ALS treatment. Credit: JHVEPhoto via Shutterstock. Eli Lilly is adding another asset

June 3, 2024

Rentschler Biopharma Appoints Patrick Cushing as VP Operations for U.S. Subsidiary – Biotech Investments

EQS-News: Rentschler Biopharma SE / Key word(s): Personnel Rentschler Biopharma Appoints Patrick Cushing as VP Operations for U.S. Subsidiary 02.05.2024 / 14:10 CET/CEST The issuer

May 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.